Preclinical research answers the first questions: whether a molecule has activity, what mechanism it acts through, how it behaves in a living organism and what toxicity it shows. It is divided into in vitro studies (cells, isolated tissues, biochemical assays) and in vivo studies (mice, rats and other species).
It is an essential stage, but its ability to predict results in humans is limited. A large proportion of substances that work in animal models do not show the same effect, or turn out to have safety problems, when they reach clinical trials.
Much of the literature on research peptides (BPC-157, TB-500, Epitalon, MOTS-c and others) is preclinical. That does not invalidate it, but it does define how far it can be taken when interpreting it.
When reading about a peptide, the first useful question is: was this seen in cells, in animals or in people? The answer completely changes the weight of the claim.
Related terms
Learn it in depth at the Peptide University
- Complementary monographs (16–20) · Module 14
- BPC-157: investigated mechanisms · Module 4
- KPV, anti-inflammatory melanocortins and combinations · Module 4
- Safety profiles by class · Module 10
- Pharmacovigilance, quality and evidence-based practice · Module 10
Related catalogue compounds
Definition for educational and scientific purposes. It is not medical advice or a recommendation for use. NeoPeptidos products are sold labelled for research use only (RUO).